Novel determinants preventing achievement of major cardiovascular targets in type 2 diabetes

Diabetes Metab Syndr. 2014 Jul-Sep;8(3):145-51. doi: 10.1016/j.dsx.2014.04.037. Epub 2014 Jun 16.

Abstract

Background: T2DM management requires tight control of 3 critical quality indicators to prevent vascular complications: LDL-C, SBP, and HbA1c. This study evaluated the rate of T2DM patients attaining these critical quality indicators, and the pathophysiological or cardiometabolic traits predicting goal achievement.

Patients and methods: Cross-sectional analysis evaluating combined goal achievement (LDL-C<100 mg/dL; SBP<130 mmHg and HbA1c<7.0%) in 1005 T2DM outpatients (654 men) followed in a university hospital multidisciplinary department. Triple-goal achievers were compared to non-achievers regarding sociodemographics; anthropometrics; homeostatic model assessment (HOMA; β-cell function (B); insulin sensitivity (S); hyperbolic product (B×S)); CV and glucose-lowering drugs; micro-/macro-vascular outcomes; and 10-year UKPDS risk.

Results: Eighty-eight patients (9%; ((3 targets) group) reached all goals, whereas 917 patients (91%; ((0-2 target(s)) group) missed 1, 2 or all 3 goals. Compared to (0-2 target(s)), (3 targets) had shorter diabetes duration; less familial diabetes history; lower waist/visceral fat; higher β-cell function and hyperbolic product (B×S); lower (B×S) loss rate and less metabolic syndrome (all p<0.05). They had lower apoB and triglycerides; and a 28% prevalence of atherogenic dyslipidemia (vs. 40% in (0-2 target(s)); p 0.0398). Microangiopathy (36% vs. 53%) and 10-year CAD risk (13% vs. 18%) were also significantly lower in (3 targets).

Conclusions: The subset of T2DM patients achieving all critical quality indicators are characterized by a less severe cardiometabolic phenotype, while exhibiting a less pronounced alteration of their residual β-cell function. These differences are related to fewer microvascular outcomes and lower 10-year CV risk.

Keywords: Glycated haemoglobin; LDL-cholesterol; Microangiopathy; Quality of care; Systolic blood pressure; Type 2 diabetes mellitus.

Publication types

  • Review

MeSH terms

  • Aged
  • Belgium / epidemiology
  • Biomarkers / metabolism
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / prevention & control*
  • Cross-Sectional Studies
  • Diabetes Mellitus, Type 2 / epidemiology
  • Diabetes Mellitus, Type 2 / metabolism*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetic Angiopathies / epidemiology
  • Diabetic Angiopathies / metabolism
  • Diabetic Angiopathies / prevention & control*
  • Dyslipidemias / metabolism*
  • Dyslipidemias / physiopathology
  • Glycated Hemoglobin / metabolism*
  • Humans
  • Insulin-Secreting Cells / metabolism*
  • Middle Aged
  • Phenotype
  • Prevalence
  • Risk Factors

Substances

  • Biomarkers
  • Glycated Hemoglobin A
  • hemoglobin A1c protein, human